Pure red cell aplasia occurring during ibrutinib therapy for chronic lymphocytic leukemia.

Our case demonstrates a need to evaluate the risk of developing AIC before initiating ibrutinib. For patients with high-risk factors for AIC episodes, the transient addition of other immunosuppressive therapies should be taken into consideration.